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doi:10.1016/j.jfma.2012.02.027Background/Purpose: Exenatide has been predominantly studied in non-Asian populations. The
purpose of this study was to investigate the safety and efficacy of twice-daily (BID) exenatide
versus placebo in a subpopulation of Taiwanese patients from a larger study on Asian patients.
Methods: Patients unable to achieve glycemic control with metformin alone or metformin in
combination with sulfonylurea were randomly assigned to self-administer either 5 mg exenatide
or placebo BID for 4 weeks, then 10 mg exenatide or placebo BID for an additional 12 weeks, in
addition to their regular oral therapy.
Results: Fifty patients from Taiwan were enrolled in this study (54.0% male; age: 50.9 9.4
years; weight: 71.0  11.6 kg; 8.1  1.0% hemoglobin A1c (HbA1c)). The exenatide-treated
patients demonstrated a statistically significant greater reduction in HbA1c from baseline to
the endpoint (least-squares [LS] mean [95% confidence interval (CI)]: -0.8% [-1.4e-0.2];
pZ 0.009) compared with patients who received placebo (LS mean [95% CI]: -0.1% [-0.7e0.4])
with an LS mean [95% CI] between-group difference of -0.7% (-1.3e-0.1) (pZ 0.025). A statisti-
cally significant higher number of exenatide-treated patients achieved HbA1c targets of  7%
(pZ 0.020) and  6.5% (pZ 0.021) by the endpoint compared with patients who received
placebo. Exenatide-treated patients experienced a statistically significant reduction inof Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan.
tw (L.-M. Chuang).
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
Exenatide treatment in Taiwanese patients 145weight from baseline to endpoint (exenatide-placebo adjustedmean difference [95% CI]: -1.6 kg
[-2.7e-0.6]; pZ 0.004) compared with the placebo group. The symptomatic hypoglycemia rate
(mean patient/year standard deviation) was higher in exenatide-treated patients (4.86 mean
patient/year 7.36) than placebo-treated patients (0.27 mean patient/year 1.32). Thirteen
(50.0%) exenatide-treated patients and nine (37.5%) placebo-treated patients reported one or
more treatment-emergent adverse events; nausea was the most frequently reported side effect
(exenatide, 4 [15.4%]; placebo, 0 [0.0%]).
Conclusion: This subgroup analysis of Taiwanese patients was consistent with the overall study
results, which showed that exenatide BID is superior to placebo for improving glycemic control in
Asian patients with type 2 diabetes who experienced inadequate glycemic control when using
oral antidiabetic therapy.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
According to the World Health Organization (WHO), more
than 180 million people worldwide have type 2 diabetes
mellitus and this number is likely to more than double
by the year 2030.1 Asia is predicted to be the center of
this epidemic.2 Rapid socioeconomic progress, as seen in
Taiwan over the past 30 years, as well as the adoption of
unhealthy lifestyles, migration to industrialized counties,
the increasing prevalence of child obesity, and other
sociocultural factors are associated with the substantial
increase in the prevalence of diabetes in Taiwan.3,4
Exenatide is a glucagon-like peptide 1 (GLP-1) agonist
that has been approved for use in a number of countries,
including the United States (for use as a monotherapy or in
combination with metformin [MET] and/or sulfonylurea
[SU] or thiazolidinedione in combination with diet and
exercise) and Europe (in combination with MET and/or SU or
in combination with thiazolidinedione and/or MET), to
improve glycemic control in patients with type 2 diabetes
mellitus who have not achieved adequate glycemic control.
Exenatide is a 39-amino acid peptide with several poten-
tially beneficial glucoregulatory actions similar to those of
the endogenous GLP-1, including reducing circulating
glucose, enhancing insulin secretion, suppressing inappro-
priately elevated glucagon secretion, decelerating gastric
emptying, and enhancing satiety.5e10 Decreased food
intake and weight loss are additional beneficial effects
associated with exenatide treatment.11e13
The majority of patients with type 2 diabetes mellitus are
already obese, which contributes to the development of
insulin resistance and lipotoxicity. Weight gain is associated
with an increased incidence of cardiovascular disease risk
factors, such as hypertension and dyslipidemia; however,
some therapies currently used to maintain and improve
glycemic control, such as thiazolidinediones, sulfonylureas,
and insulins, are associated with weight gain.14 Potential
weight gain in association with glycemic control therapy can
be a major barrier to successful treatment compliance.15
The safety and efficacy of exenatide has been predomi-
nantly studied in non-Asian populations.11e13,16e18 However,
the results of a clinical study (ClinicalTrials.gov registration
no. NCT00324363) that investigated the safety and efficacy
of exenatide in Asian countries have recently been pub-
lished.19 The objective of this double-blind, placebo-
controlled, randomized, two-arm, parallel study was to testthe hypothesis that exenatide, when taken twice-daily
(BID) before morning and evening meals, produces
a greater baseline-to-endpoint reduction in glycosylated
hemoglobin (HbA1c) than placebo BID after 16 weeks of
treatment in Asian patients with type 2 diabetes mellitus
that was inadequately controlled using MET alone or MET in
combination with SU.
Because Taiwan is culturally and geographically distinct
from other Asian countries, a subanalysis was conducted
to investigate the efficacy and safety of exenatide in
Taiwanese patients, the results of which are presented
here.
Materials and methods
Patients were recruited to participate in this double-blind,
placebo-controlled, randomized, two-arm, parallel study
from four Asian countries (China, India, Korea, and Taiwan)
between January 2006 and February 2007. This report
presents data related to the 51 randomized patients
recruited from Taiwan.
All patients (both women and men) enrolled in this study
were between 21e75 years of age (inclusive), met the WHO
criteria for type 2 diabetes mellitus, had been treated with
a stable dose of MET alone or in combination with SU for at
least 3 months prior to screening, and demonstrated
suboptimal glycemic control (HbA1c between 7.1e11.0%,
inclusive).20
Patients were not eligible for enrollment if they had been
treated with exogenous insulin for more than 1 week within
the 3 months prior to screening, had a clinically significant
history of cardiac or renal disease, demonstrated active
cardiac disease within 1 year prior to inclusion in the study,
had a history of renal transplantation, were currently
receiving renal dialysis, or had an elevated serum creatinine
level ( 133 mmol/L for men or  106 mmol/L for women).
Patients receiving thiazolidinediones, meglitinide deriv-
atives, alpha-glucosidase inhibitors, systemic corticoste-
roids, or drugs that directly affect gastrointestinal motility
were also excluded. Pregnant or breastfeeding women
were not eligible, and all women of childbearing potential
were required to use an approved method of birth control.
This study (ClinicalTrials.gov registration no. NCT00324363)
was approved by the ethical review board of each
participating hospital and carried out in accordance with
the ethical principles of the Declaration of Helsinki and
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and regulations. All patients provided signed informed
consent before undergoing any study procedures.
After a 1-week screening period, the patients entered
a 2-week, single-blind, placebo lead-in period to acclima-
tize those who were injection-naı¨ve. On the third visit,
patients were stratified by investigative site and current
treatment (MET or MET/SU) and randomly assigned with
equal probability to one of two treatment groups (current
treatment plus exenatide or current treatment plus
placebo) by a computer-generated randomization sequence
using an interactive voice response system.
In addition to their regular glycemic control treatment
regimen (MET or MET/SU), patients were required to self-
administer an injection of 5 mg (in 20 mL of solution) BID of
exenatide or 20 mL placebo for the first 4 weeks of therapy
followed by 10 mg (in 40 mL of solution) BID of exenatide or
40 mL placebo for an additional 12 weeks of therapy.
The primary outcome of this study was the baseline-
to-endpoint reduction in HbA1c obtained by exenatide versus
placebo BID after 16 weeks of treatment. Secondary
outcomes included the proportion of patients who achieved
a HbA1c target of  7% and  6.5%, changes in body weight,
fasting plasma glucose (FPG), a 7-point self-monitored blood
glucose (SMBG) profile, and the safety and tolerability of
exenatide versus placebo (as measured by the incidence and
rate of hypoglycemic events, treatment-emergent adverse
events [TEAEs], and clinical laboratory analytes).
Hypoglycemic episodes were defined as any time
a patient experienced a sign or symptom of hypoglycemia
with or without a documented blood glucose level of
< 3.3 mmol/L (60 mg/dL) during self-monitoring or treat-
ment. Severe hypoglycemia was defined as an episode of
symptoms that required the assistance of another person
and was associated with either a glucose level of
< 2.8 mmol/L (50 mg/dL) or prompt recovery after the
administration of oral carbohydrates, intravenous glucose,
or intramuscular glucagon.
Efficacy and safety analyses were conducted on the full
analysis set (FAS), which included all randomized patients
who self-administered at least one dose of the study drug.
Efficacy analyses were also performed on the per-protocol
analysis set (PPS) for supportive evidence. All statistical
tests were performed at a level of significance of 0.05. No
adjustments were made for multiplicity. Missing data were
not included in the analysis, except for the last observation
carried forward (LOCF) of the postbaseline values.
Treatment comparisons of the primary and secondary
efficacy measures were made using the analysis of covari-
ance model, including treatment, pooled investigator, oral
antidiabetic therapy (OAD) stratum, and baseline values of
the dependent variables as covariates. Least-squares (LS)
means with 95% confidence intervals (CI) were produced to
estimate the treatment effects. The superiority of exena-
tide was demonstrated if an LS mean indicated a greater
reduction in HbA1c for exenatide than placebo and
a p value of < 0.05 (2-sided) was determined. The
percentage of patients who achieved the target HbA1c
value ( 7%) at the endpoint was summarized and the
differences in the proportions between the treatment
groups was examined using logistic regression in terms of
treatment, OAD stratum, and baseline HbA1c.Results
Patient disposition and baseline characteristics
In Taiwan, 51 patients were randomly assigned to the two
treatment groups. Of these patients, 26 received exenatide
BID (exenatide group), 24 received placebo (placebo
group), and one patient (assigned to the placebo group) was
dropped from the study prior to taking the first dose of the
study therapy. Forty-four (88.0%) patients completed the
16-week treatment period (placebo group: 20 [83.3%];
exenatide group: 24 [92.3%]). Details regarding patient
disposition are presented in Fig. 1.
The baseline demographic characteristics are similar
between the two treatment groups (Table 1). At baseline,
54.0% of patients were men and demonstrated a mean
standard deviation (SD) of 50.9 9.4 years of age,
27.2 3.3 kg/m2 body mass index (BMI), 8.1 1.0% overall
HbA1c, and a history of diabetes of 7.6 4.9 years.
Seventy-two percent of patients had a BMI 25.
With respect to OAD medication, the majority of
patients were taking MET/SU at baseline (Table 1). The
average daily dose of MET at baseline was similar between
groups (1706 mg/day for the placebo group vs. 1692 mg/day
for the exenatide group).
Efficacy measures
Patients treated with exenatide experienced a statistically
significant reduction in HbA1c from baseline to the
endpoint (LS mean [95% CI]: -0.8% [-1.4e-0.2]; pZ 0.009),
while no significant difference was observed in the placebo
group (LS mean [95% CI]: -0.1% [-0.7e0.4]; Table 2). A
statistically significant mean LS between-treatment
difference (exenatide-placebo) in HbA1c from the base-
line of -0.7% (95% CI: -1.3e-0.1; pZ 0.025) was observed at
the endpoint.
A statistically and significant greater percentage of
exenatide-treated patients reported endpoint HbA1c
targets of  7% (exenatide: 56.5%; placebo: 26.1%;
pZ 0.020) and  6.5% (exenatide: 42.3%; placebo: 13.0%;
pZ 0.021) compared with placebo-treated patients.
After 16 weeks of treatment, exenatide-treated patients
demonstrated statistically significant reductions in body
weight from the baseline (LS mean [SEM] change of
-1.99 0.53 kg) compared with placebo-treated patients
(LS mean [SEM] change of -0.37 0.50 kg; p< 0.001). A
statistically significant mean LS between-treatment
difference (exenatide-placebo) in terms of body weight
reduction from baseline of -1.6 kg (95% CI: -2.7e-0.6;
pZ 0.004) was observed at the endpoint.
Baseline-to-endpoint reductions in fasting plasma
glucose were not significantly different between the two
treatment groups (Table 2). The 7-point self-monitored
blood glucose profiles of the Taiwanese patients (Fig. 2)
were less variable at the endpoint than at baseline among
patients treated with exenatide, but not among patients
treated with placebo. At the end of the study, the LS mean
differences (95% CI; exenatide-placebo) in terms of the
SMBG values were -3.63 (-5.18e-2.07; p< 0.001), -0.27
(-1.72e1.18; pZ 0.710), and -2.29 (-3.99e-0.59; pZ 0.009)
Patients entered
n = 71
Discontinued prior to randomization, n = 2
Exenatide plus OAD
FAS, n = 26 
Placebo plus OAD 
FAS, n = 24
CompletedCompleted
n = 24 
PPS, n = 23
Patients randomized
n = 51
Discontinuations, n = 2
adverse event (n = 1)
patient decision (n = 1)
Patients entering placebo lead in
n= 53
Discontinuations, n = 4
protocol entry criteria not met (n = 1)
patient decision (n = 2)
lack of efficacy (n = 1)
Screen failures, n = 18
protocol entry criteria not met (n = 14)
other (n = 4) 
Discontinued prior to first dose of study drug, n = 1
protocol entry criteria not met (n = 1)
•
•
•
•
•
•
•
•
n = 20 
PPS, n = 20
Figure 1 Patient disposition. Abbreviations: FAS, full analysis set (data from all randomized patients receiving at least 1 dose of
the study medication); n, number of patients; OAD, oral antidiabetic drug; PPS, per-protocol analysis set (data from all randomized
patients receiving at least 16 weeks of exposure to the study medication who also had no violations of study criteria).
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points, respectively. The LS mean difference (95% CI;
exenatide-placebo) for the daily mean at the end of the
study was -1.03 (-2.04e-0.02; pZ 0.046). These results are
similar to those of the patients in the overall population.Safety
In this Taiwanese patient population, 13 (50.0%) exenatide-
treated patients and nine (37.5%) placebo-treated patients
reported one or more TEAEs. The most frequently reportedTable 1 Baseline characteristics and disease severity of
all Taiwanese randomized patients.
Exenatide
(NZ 26)
Placebo
(NZ 24)
Gender, male/female 14/12 13/11
Age, y SD 50.5 9.0 51.3 9.9
Duration of diabetes, y SD 6.7 3.9 8.5 5.7
HbA1c group, n (%)
HbA1c < 8.5 18 (69.2) 16 (66.7)
HbA1c  8.5 8 (30.8) 8 (33.3)
Weight, kg SD 71.6 8.9 70.4 14.1
BMI group, n (%)
Normal: 18.5  BMI < 23 2 (7.7) 3 (12.5)
Overweight: 23  BMI < 25 4 (15.4) 5 (20.8)
Obese: BMI 25 20 (76.9) 16 (66.7)
Treated with MET, n (%) 2 (7.7) 3 (12.5)
Treated with MET þ SU, n (%) 24 (92.3) 21 (87.5)
Abbreviations: BMI, body mass index; HbA1c, glycosylated
hemoglobin; MET, metformin; N, total number of patients;
n, number of patients; SD, standard deviation; SU, sulfonylurea.(total incidence  5) TEAEs included nausea (exenatide, 4
[15.4%]; placebo, 0 [0.0%]), cough (exenatide, 2 [7.7%];
placebo, 1 [4.2%]), diarrhea (exenatide, 2 [7.7%]; placebo,
1 [4.2%]), constipation (exenatide, 2 [7.7%]; placebo,
0 [0.0%]), decreased appetite, (exenatide, 2 [7.7%];
placebo, 0 [0.0%]), and dizziness (exenatide, 2 [7.7%];
placebo, 0 [0.0%]).
Of the four exenatide-treated patients who experienced
nausea, one case was of mild severity and three cases were
of moderate severity (3.8% and 11.5%, respectively). The
highest incidence of nausea was reported when patients
initiated 5 mg exenatide at week 0 and increased the dose
to 10 mg at week 4. One patient (3.8%) was dropped from
the study due to diarrhea, which started the day after
initiating exenatide therapy and was moderate in intensity.
No deaths occurred during this study.
The incidence of symptomatic hypoglycemic episodes
was numerically higher among exenatide-treated patients
(12 [46.2%]) compared with placebo-treated patients
(1 [4.2%]). The symptomatic hypoglycemia rate per patient
(mean SD), when adjusted for 30 days, was higher in the
exenatide group (0.40 0.61) than the placebo group
(0.02 0.11) after 16 weeks of treatment; when adjusted
for 1 year, the symptomatic hypoglycemia rate per patient
(mean SD) was 4.86 7.36 among exenatide-treated
patients compared with 0.27 1.32 for placebo-treated
patients.
All hypoglycemic episodes were reported by patients
taking a combination of MET plus SU; however, only five
patients in Taiwan were administered MET alone. No
patients in Taiwan experienced a severe hypoglycemic
episode during this study.
The relationship between the development of anti-
exenatide antibodies and glycemic control was also
examined. Among patients who tested positive (nZ 9) or
negative (nZ 17) for anti-exenatide antibodies, the change
Table 2 Summary of baseline-to-endpoint mean changes of the efficacy measures.
Exenatide (NZ 26) Placebo (NZ 24)
HbA1c (%)
Baseline, mean SD 8.1 1.0 8.1 1.0
Endpoint D, LS mean (95% CI) -0.8 (-1.4e-0.2) -0.1 (-0.7e0.4)
Fasting plasma glucose, mmol/L
Baseline, mean SD 9.1 2.4 9.1 2.8
Endpoint D, LS mean (95% CI) -0.6 (-2.3e1.0) -0.3 (-1.9e1.3)
Body weight, kg
Baseline, mean SD 71.6 8.9 70.4 14.1
Endpoint D, LS mean (95% CI) -2.0 (-3.1e-0.9) -0.4 (-1.4e0.6)
Mean daily glucose,a mmol/L
Baseline, mean SD 10.8 2.9 10.8 2.4
Endpoint, LS mean SE 8.2 0.5 9.2 0.5
Abbreviations: D, change from baseline; CI, confidence interval; HbA1c, glycosylated hemoglobin; LS, least-squares; N, total number of
patients; SD, standard deviation; SE, standard error.
a The values for mean daily glucose are not the mean change.
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between groups (mean adjusted change from baseline [95%
CI]: positive, -0.3% [-1.6e0.9]; negative, -0.2% [-1.7e1.2]).Figure 2 Summary of the 7-point self-monitored blood
glucose (SMBG) profile at baseline and last-observation-
carried-forward (LOCF) endpoint for (A) the exenatide group
and (B) the placebo group. Descriptive means (standard error
of the mean [SEM]) for SMBG concentrations at baseline and
endpoint (week 16 or early discontinuation [LOCF]) from the
full analysis set).Discussion
The results of this subanalysis of Taiwanese patients
demonstrates that exenatide BID is superior to placebo for
the management of glycemic control in patients with type 2
diabetes mellitus who failed to achieve control on OADs
after 16 weeks of treatment. These findings are consistent
with results of the overall study on patients in both East and
West Asia and similar trials that have been performed on
non-Asian populations: specifically, a significant reduction
in HbA1c was observed and significantly more exenatide-
treated patients were able to meet the HbA1c targets
of  7% and  6.5% when compared with placebo-
treated patients at the endpoint.11e13,19 No patients in
the Taiwanese subset discontinued participation in the
study due to the lack of efficacy; however, one patient
discontinued treatment due to adverse effects.
Exenatide-treated Taiwanese patients experienced
a significantly greater reduction in mean body weight
compared with placebo. It is interesting to note that of the
four countries (China, India, Korea, and Taiwan) that
participated in the overall study, patients in Taiwan expe-
rienced the largest reduction in body weight by the study
end; however, due to the small sample size, additional
studies are required to further investigate this finding. The
significant reduction in body weight observed among
exenatide-treated patients in Taiwan are in accordance
with previous studies on both non-Asian and Asian pop-
ulations, suggesting that reductions in body weight cannot
be attributable to ethnic differences but may be a consis-
tent result of exenatide treatment.11e13,19 These data
support previously published results indicating the addi-
tional benefit of exenatide over other glycemic control
therapies, such as insulin, which are often correlated with
weight gain.11e13,16e18,21 Additional weight gain in patients
with type 2 diabetes mellitus who are already overweight or
obese can also have a negative impact on treatment
compliance and quality of life.15
In Taiwan, as in the overall study, more exenatide- than
placebo-treated patients reported TEAEs.19 The most
frequently reported TEAE was nausea of mild to moderate
severity, which decreased over time, a finding that is
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data obtained in the overall study.11e13,19,22
Taiwanese patients reported a lower overall rate of
TEAEs, including a lower rate of nausea in comparison with
the overall population, but Taiwanese patients also re-
ported the highest incidence of nausea when initiating 5 mg
exenatide (week 0) and at week 4. Whereas, in the overall
study, the highest incidence of nausea was reported when
patients increased the exenatide dose from 5 mg to 10 mg
(week 4) and at week 8. It is possible that these disparities
may be due to ethnic differences between countries;
however, due to the small sample size, further studies are
necessary to confirm this hypothesis. Initiating exenatide
therapy at a lower dose could be a potential option that
clinical practices should consider in Taiwan, but further
studies are required to verify this hypothesis.
In Taiwan, the largest meal of the day is traditionally
dinner; however, Taiwanese patients demonstrated
a similar SMBG profile to that of patients in the overall Asian
population. This suggests that meal patterns may not be so
different between the four countries that were investi-
gated, or it may be that the efficacy of exenatide is unaf-
fected by variations in meal size.19,23
In both the overall study population and the Taiwanese
subset, the incidence of symptomatic hypoglycemic episodes
was higher among exenatide-treated patients compared
with the placebo group. The incidence of hypoglycemic
episodes was higher among patients taking a combination
of MET/SU in the Taiwanese subset and in the overall study
population. In the Taiwanese population, however, only
a small number of patients were taking MET alone. No
Taiwanese patient experienced severe hypoglycemia.
The main limitation of this analysis is the small number
of Taiwanese patients who participated in this study. The
findings and conclusions drawn from these country-specific
results should, therefore, be evaluated and interpreted
with consideration to the overall study results.
In conclusion, the findings of this subgroup analysis of
Taiwanese patients are consistent with the overall study
results, which show that exenatide (10 mg/day BID) is supe-
rior to placebo for improving glycemic control in patients
with type 2 diabetes mellitus who experienced inadequate
glycemic control with OAD therapy (MET alone or MET in
combination with SU).
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